Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai L,

Jiang C,

Zhang G,

Fang H,

Wang J,

Li Y,

Xu H,

Xiao R,

Ding Y,

Huang K,

Zhang C,

Zhang L,

Chen B,

Duan X,

Pan W,

Han G,

Chen R,

Liu L,

Zhang S,

Tao J,

Pang X,

Yu J,

Wang H,

Zhao Y,

Li C,

Kang X,

Qin L,

Zhu X,

Su J,

Li S,

Yang C,

Feng W,

Lei T,

Jiang S,

Fang R,

Lin M,

Lu Q,

Xu C,

Wang W,

Zhang J

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

March 2019

Baricitinib Induces LDL-C and HDL-C Increases in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials

Lipids Health Dis. 2019 Feb 18;18(1):54.

Qiu C,

Zhao X,

She L,

Shi Z,

Deng Z,

Tan L,

Tu X,

Jiang S,

Tang B

This study confirmed that BARI induced a stable dose-dependent increase in LDL-C and HDL-C levels. There was no significant difference of CV risk between BARI and placebo groups.High risk of CV events is strongly associated with RA. Mechanisms underlying the excess risk of CV events in RA remains unclear. This study aims to provide additional insight into the clinical safety of BARI, focusing on the effects of BARI on LDL-C and HDL-C levels and CV risk. A Cochrane analysis was performed on studi...